

Contents

Series Introduction	iii
Preface	v
Contributors	..:
Medical Biotechnology: A Brief Historical Survey <i>Michel Bernon and Jacques Bodelle</i>	xv
I. EXPERIENCES OF THE PAST	
1. BIOLOGICAL PRODUCTION SYSTEMS	
I. Stability of Recombinant Plasmids for Production of Heterologous Proteins in <i>Escherichia coli</i> <i>Charles L. Hershberger and Paul R. Rosteck, Jr.</i>	3
II. Recombinant Yeast as a Production System in Biotechnology <i>Bernardita Méndez and Pablo Valenzuela</i>	16
III. The Preparation and Validation of Stock Cultures of Mammalian Cells <i>Thomas J. Facklam and Scott Geyer</i>	54
IV. Genetic and Molecular Studies to Certify Seed Pools and Production Fermentations of Industrial <i>Escherichia</i> <i>coli</i> Strains <i>Charles L. Hershberger and Paul R. Rosteck, Jr.</i>	86
2. PRODUCTION FACILITIES	
I. Fermenters for Prokaryotic Cells <i>William L. Muth</i>	103
II. Bioreactor and Process Design for Large-Scale Mammalian Cell Culture Manufacturing <i>Kim L. Nelson and Scott Geyer</i>	112
	vii

III. Automatic Control Systems <i>Joseph S. Alford, Jr.</i>	144
3. DRUG MANUFACTURE	
I. Fermentation Processes for Prokaryotic Cells <i>William L. Muth</i>	155
II. Yeast Fermentation Processes for Insulin Production <i>Ivan V. Diers, Eigil Rasmussen, Per Henrik Larsen, and Inge-Lise Kjaersig</i>	166
III. Industrial Scale Mammalian Cell Culture <i>Robert Arathoon and T. G. Hughes</i>	177
IV. Postbiosynthesis Modification: Human Growth Hormone and Insulin Precursors <i>Thorkild Christensen, Henrik Dalbøge, and Leo Snel</i>	206
V. Production-Scale Purification Processes <i>Walter F. Prouty</i>	221
4. CHARACTERIZATION OF PROTEINS FROM RECOMBINANT DNA MANUFACTURE <i>Robert L. Garnick, Michael J. Ross, and Robert A. Baffi</i>	263
5. FOOD AND DRUG ADMINISTRATION INSPECTION AND LICENSING OF MANUFACTURING FACILITIES <i>Henry L. Avallone, Michael G. Beatrice, and Thaddeus T. Sze</i>	315
6. SAFETY AND EFFICACY EVALUATION OF RECOMBINANT DNA PRODUCTS	
I. Scientific and Regulatory Considerations in the Development of Human Growth Factors <i>G. Alexander Fleming, Alexander W. Jordan, and Yuan-yuan H. Chiu</i>	341
II. Recombinant Yeast-Derived Hepatitis B Vaccine: The Prototype for Biotechnologically Derived Old Vaccines <i>Ronald W. Ellis</i>	355
7. INDUSTRY'S VIEW ON GOVERNMENT REGULATORY ACTIVITIES	
I. Industry's Experience with Worldwide Regulation of Biotechnology Products <i>Alan Dinner and John M. Fose</i>	371
II. Culturing a Biotech Company in a Regulatory Medium <i>Robert A. Swanson</i>	382

II. FUTURE PROSPECTS

8. POTENTIALLY USEFUL BIOLOGICAL PRODUCTION SYSTEMS	
I. Fungi as Bioprocessing Systems for the Production of Pharmaceutically Important Proteins	391
<i>David I. Gwynne and Nigel J. Smart</i>	
II. Baculovirus Expression Systems and Insect Cells	402
<i>Jennifer A. Jackson</i>	
9. SECOND-GENERATION PRODUCTS	
I. Second-Generation Products: Antibiotics	415
<i>Jeffrey T. Fayerman</i>	
II. Novel Approaches for the Production of Biotechnologically Derived Vaccines of the Future	425
<i>Ronald W. Ellis</i>	
III. Advances Toward Somatic Cell Gene Therapy	439
<i>Dvorit Samid, W. French Anderson, and Robert C Moen</i>	
10. INTERNATIONAL HARMONIZATION AMONG WORLDWIDE REGULATORY AGENCIES	
I. Harmonization of Biotechnological Regulations in the European Community	455
<i>Fernand Sauer</i>	
II. The Japanese Perspective Regarding Regulatory Concerns for Biotechnology Drugs and Their Scientific Basis	468
<i>Takao Hayakawa</i>	
III. Regulatory Evaluation of Biotechnology Drugs: Current Trends in the United States	400
<i>Solomon Sobel</i>	
11. A SCENARIO FOR THE FUTURE: BIOTECHNOLOGY AND PHARMACOGENESIS	513
<i>John L. Gueriguan, Yuan-yuan H. Chiu, Dominic P. Gangi, and Geoffroy d'Aumale</i>	
APPENDIX A Compilation of Government Regulation of Biotechnology	525
<i>Joseph Paul Hile, Barbara H. Keech, C. K. Gund, and Wendy M. Connolly</i>	
Index	545